Palatin Technologies, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended June 30, 2015. Although the request metadata refers to “2014 Q4,” this filing is the company’s annual report for fiscal 2015; it also reports fourth-quarter results for the three months ended June 30, 2015. Financial statements were audited by KPMG, which issued an unqualified opinion.
Business context
Palatin is a development-stage biopharmaceutical company with no products currently generating sales. Its lead candidate, bremelanotide, was in Phase 3 trials for female sexual dysfunction (FSD). Other programs included PL-3994 for cardiovascular and pulmonary indications, and preclinical melanocortin programs for inflammatory, dermatologic, obesity and metabolic conditions.
Key financial metrics
| Metric | FY2015 | FY2014 |
|---|---|---|
| Revenue | $13.0 million | $0 |
| Research and development expense | $24.6 million | $10.8 million |
| General and administrative expense | $5.7 million | $5.0 million |
| Operating loss | $17.3 million | $15.8 million |
| Net loss | $17.7 million | $13.9 million |
| Net loss per share | $0.15 | $0.13 |
| Cash used in operating activities | $13.4 million | $12.2 million |
Revenue was entirely from the Gedeon Richter license and development milestone payments. FY2015 included a $0.5 million New Jersey tax benefit; FY2014 included a $1.8 million benefit. Fourth-quarter FY2015 revenue was zero and net loss was $12.1 million; the preceding two quarters included license revenue.
At June 30, 2015, cash and cash equivalents were $27.3 million, total current assets $29.2 million, current liabilities $7.4 million, total liabilities $17.3 million and stockholders’ equity $12.2 million. Notes payable were $10.0 million principal, reported net of discount at $9.8 million. The four-year secured loan carries interest at one-month LIBOR, subject to a 0.50% floor, plus 8.50%; principal payments were scheduled after an 18-month interest-only period. The company reported an accumulated deficit of $291.7 million.
Changes versus the prior comparable period
- Revenue rose from zero to $13.0 million, reflecting the Gedeon Richter agreement; it was collaboration-related, not product sales.
- R&D expense more than doubled, principally because Palatin initiated Phase 3 bremelanotide trials. Net loss increased by $3.7 million.
- Cash rose from $12.2 million to $27.3 million, supported by a December 2014 equity placement and $10.0 million venture loan, partly offset by operating cash use.
- Common shares outstanding at fiscal year-end increased to 57.1 million from 39.4 million a year earlier. The filing also discloses substantial warrant-related potential dilution.
Outlook, risks and unusual items
- Palatin expected bremelanotide Phase 3 enrollment to finish in 2015 and projected topline results in the third quarter of calendar 2016. The company said the Phase 3 program, including an NDA submission, would cost at least $80 million.
- After fiscal year-end, on July 2, 2015, the company raised $20.0 million gross in a warrant private placement and closed a further $10.0 million venture loan. Management said cash resources, including these financings, were expected to fund planned operations through the quarter ending September 30, 2016. Additional funding would still be needed to complete the bremelanotide program and advance other candidates.
- On September 16, 2015, Palatin and Gedeon Richter terminated their license and co-development agreement by mutual agreement. Rights reverted to Palatin; neither party had material future obligations or termination payments. Palatin stated it was seeking potential commercialization partners.
- Management expects continuing losses and no near-term profitability. Key uncertainties include Phase 3 efficacy and safety, FDA review, ability to raise capital, partner availability, reimbursement and market acceptance, and reliance on third-party clinical and manufacturing providers.
- PL-3994 was ready for Phase 2 safety and efficacy studies; planned trials were contingent on adequate funding. Palatin anticipated filing an IND for PL-8177 as early as the first half of calendar 2016, also subject to available funds.
- Other notable items: FY2015 included $0.7 million interest expense, primarily related to venture debt, and a $0.3 million foreign-exchange loss. No material legal proceedings or off-balance-sheet arrangements were reported.
Important facts for investors to verify
- Whether Phase 3 bremelanotide enrollment, results and safety outcomes met the stated timeline and support an NDA.
- Current cash, operating burn, debt service and financing runway compared with the stated September 2016 horizon and the estimated $80 million program cost.
- Consequences of the Gedeon Richter termination, including any replacement partner, licensing economics and commercialization plans.
- The potential dilution and financing constraints associated with warrants, preferred stock and investors’ rights to participate in future financings.
- Progress, funding and timing for PL-3994 and PL-8177, and whether any planned clinical studies began.